Form 8-K - Current report:
SEC Accession No. 0001798749-24-000055
Filing Date
2024-10-17
Accepted
2024-10-17 16:59:05
Documents
13
Period of Report
2024-10-11
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tmb-20241011x8k.htm   iXBRL 8-K 42424
  Complete submission text file 0001798749-24-000055.txt   166377

Data Files

Seq Description Document Type Size
2 EX-101.SCH tmb-20241011.xsd EX-101.SCH 3127
3 EX-101.LAB tmb-20241011_lab.xml EX-101.LAB 16581
4 EX-101.PRE tmb-20241011_pre.xml EX-101.PRE 10783
15 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20241011x8k_htm.xml XML 5090
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 241378193
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)